Breaking Down Zhejiang Jolly Pharmaceutical Co.,LTD Financial Health: Key Insights for Investors

Peeling back the numbers behind Zhejiang Jolly Pharmaceutical Co., LTD (300181.SZ) reveals a company with accelerating top-line momentum-Q3 2025 revenue of CNY 680.26 million (up 10.32% QoQ) and TTM revenue of CNY 2.81 billion (up 11.51% YoY)-while 2024 annual sales jumped to CNY 2.58 billion (a 32.71% rise from 2023); profitability signals are robust with a net profit margin of 20.02% and an operating margin of 26.05%, supported by a gross margin of 60.20% and eye-catching operating cash flow metrics (operating cash flow CNY 297 million, cash equivalents CNY 805 million, and an OCF margin of 471.72%); balance-sheet dynamics show prudent deleveraging (debt-to-equity down to 20.3% over five years, gearing 31.46%), an enterprise value near CNY 12.83 billion, and planned bond issuance of up to CNY 1.6 billion to fund capacity projects, while valuation and market signals-market cap around CNY 12.79 billion with a stock price of CNY 18.14 (Dec 12, 2025), trailing P/E 24.03 and forward P/E 19.77, P/S ~4-4.88 and P/B 4.21-pair with low beta (0.15), dividend yield 3.28% (CNY 0.60/share), and operational investments (capex CNY 262.9 million, digital workshop coming online) that set the stage for deeper analysis of risks-competition, raw-material volatility, regulatory shifts-and growth levers such as product diversification, R&D focus, market expansion and hospital collaborations; dive into the full article for the detailed breakdown and what these precise metrics mean for investors today

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) - Revenue Analysis

Zhejiang Jolly Pharmaceutical's recent top-line performance shows acceleration across quarterly and annual horizons, supported by productivity metrics and market valuation indicators.

• Q3 2025 revenue: CNY 680.26 million - a sequential increase of 10.32% from Q2 2025.
• Trailing twelve months (TTM) revenue: CNY 2.81 billion - up 11.51% year-over-year (YoY).
• Full-year 2024 revenue: CNY 2.58 billion - a 32.71% increase vs. 2023.
• Revenue per employee: CNY 1.32 million (total employees: 2,125).
• Price-to-sales (P/S) ratio: 4.26.
• Market capitalization: CNY 11.99 billion; share price: CNY 17.33 (as of 20 Nov 2025).

Key revenue drivers and positioning for investors:

• Recent sequential growth (Q3 +10.32%) suggests regained momentum after earlier quarters.
• Strong YoY expansion in 2024 (32.71%) underpins the elevated TTM growth of 11.51% despite normalization after a high-growth year.
• Revenue per employee of CNY 1.32M indicates operational scale and workforce productivity relative to peers.
• P/S of 4.26 reflects a market premium - investors price in growth and margin potential; market cap CNY 11.99B anchors valuation context.

For company positioning, strategy, and stated long-term aims, see: Mission Statement, Vision, & Core Values (2026) of Zhejiang Jolly Pharmaceutical Co.,LTD.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) - Profitability Metrics

• Net profit margin (TTM): 20.02%
• Operating margin (TTM): 26.05%
• Gross profit margin: 60.20%
• Return on assets (TTM): 9.34%
• Return on equity (TTM): 18.23%
• Diluted EPS (TTM): CNY 0.79
• Operating cash flow margin: 471.72%
• Net income (2024): CNY 507.77 million - +32.60% year-over-year

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) - Debt vs. Equity Structure

• Five-year trend: debt-to-equity ratio improved from 23.8% to 20.3%, signaling gradual de-leveraging and/or equity growth relative to debt.
• Gearing ratio: 31.46%, indicating the proportion of debt financing relative to total capital employed.
• Planned bond issuance: up to CNY 1.6 billion to fund specific projects and strengthen capital base.
• Market capitalization: CNY 12.79 billion (as of December 11, 2025).
• Enterprise value (EV): CNY 12.83 billion (as of July 1, 2025).
• Valuation multiples: P/B ratio 4.21; EV/Revenue 4.34; EV/EBITDA 16.97.

• Implication: moderate EV relative to market cap suggests market pricing close to enterprise value; planned bond proceeds will moderately increase leverage if fully used, but the five-year improvement in debt-to-equity provides cushion.
• Watchpoints: size and tenor of the CNY 1.6 billion issuance, use-of-proceeds for ROI, and any changes to EBITDA that would affect EV/EBITDA coverage.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) - Liquidity and Solvency

• Cash and cash equivalents: CNY 805.0 million
• Total debt: CNY 426.0 million
• Operating cash flow: CNY 297.0 million
• Capital expenditures (CapEx): CNY 262.9 million
• Cash flow margin: 471.72%
• Dividend payout: CNY 0.60 per share (yield 3.28%); ex-dividend date: May 26, 2025
• Beta: 0.15 (low volatility vs. market)
• Current and quick ratios: not explicitly reported but can be inferred as healthy given strong cash buffers and positive operating cash flow

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) - Valuation Analysis

Key valuation metrics for Zhejiang Jolly Pharmaceutical Co.,LTD as of December 11-12, 2025 indicate a company priced at a premium relative to history and many peers, but with forward earnings multiple suggesting expected growth. Below are the primary market and valuation figures investors should weigh.

• Valuation context: Trailing P/E of 24.03 vs forward P/E of 19.77 implies analysts expect ~20-25% improvement in earnings power (all else equal) or a re-rating based on growth catalysts.
• Relative richness: P/S of 4.88 and P/B of 4.21 show the market pays a significant premium to sales and book - common in specialty pharma but signaling higher growth expectations.
• Cash-flow perspective: EV/EBITDA of 16.97 suggests a moderate premium compared with broader healthcare indices; this reflects profitability and anticipated margin expansion.
• Market size: Market cap of CNY 12.79 billion positions the company in the mid-cap segment, with an 11.10% one-year market-cap gain indicating positive investor sentiment over the past 12 months.

For strategic context and corporate direction that may underpin these valuation levels, see the company's stated priorities here: Mission Statement, Vision, & Core Values (2026) of Zhejiang Jolly Pharmaceutical Co.,LTD.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) - Risk Factors

• Intense industry competition: domestic generics and international specialty players increase pricing pressure and may compress gross and net margins.
• Raw material price volatility: active pharmaceutical ingredients (APIs) and chemical intermediates are exposed to commodity and supply-chain shocks that raise production costs.
• Regulatory risk: changes in drug approval timelines, Good Manufacturing Practice (GMP) requirements, reimbursement and price-control policies can delay product launches or limit market access.
• Foreign exchange exposure: although mainly RMB-denominated, any export growth or import of APIs exposes earnings to FX swings (USD/EUR/CNY movements).
• Financial leverage risk: announced or planned debt issuance could raise interest expense and leverage, increasing vulnerability to rate rises and cash-flow stress.
• Operational/capex execution risk: expansions of production capacity and technology upgrades require timely delivery and cost control; overruns can depress returns and tie up cash.

• Price & margin sensitivity: a 5-10% sustained increase in key API costs or a 1-2 percentage-point decline in gross margin could materially reduce operating profit given current cost structure.
• Leverage scenarios: if planned debt issuance raises debt/equity above 0.7, interest coverage and liquidity buffers could tighten, particularly if revenue growth stalls.
• Regulatory shock scenarios: delays in approvals or GMP remediation at a major facility could curtail sales and force incremental capital spending.
• FX & export exposure: a 5-10% depreciation of RMB vs USD could raise import costs for APIs; conversely, it may boost competitiveness of exports but also strain imported-equipment costs for capex.

Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ) - Growth Opportunities

Zhejiang Jolly Pharmaceutical is positioning multiple strategic levers to accelerate growth, combining capital raising, capacity expansion, market development and R&D-driven product diversification.

• Planned capital raise: up to CNY 1.6 billion via bond issuance to fund capex and working capital for strategic projects.
• Production upgrade: a digital workshop for solid pharmaceutical preparations is scheduled to be operational by the end of the year, aimed at improving yield, quality control and throughput.
• Market expansion: deliberate strengthening of commercial efforts around core products to broaden penetration in existing and adjacent therapeutic markets.
• Medical services participation: involvement in Deqing No.3 People's Hospital to gain clinical insights, improve product adoption pathways and explore service-product synergies.
• Diversified portfolio: a mix of traditional Chinese medicines and modern pharmaceuticals provides multiple R&D and commercialization routes.
• R&D focus: continued investment in research and development to support innovation and new product launch potential.

Key operational and investment metrics tied to these growth initiatives:

• Capital allocation priorities: management signals bond proceeds will prioritize the digital workshop, targeted promotional spend for core products, and selected R&D programs to accelerate return on invested capital.
• Operational execution risks: successful realization of projected capacity gains depends on timely commissioning, quality validation and regulatory approvals for new production lines.
• Commercial upside: closer ties with Deqing No.3 People's Hospital and intensified market expansion could shorten the sales cycle for new/updated formulations and increase prescription uptake.

For a concise overview of Zhejiang Jolly Pharmaceutical's long-term mission and values that guide these growth moves, see: Mission Statement, Vision, & Core Values (2026) of Zhejiang Jolly Pharmaceutical Co.,LTD.